Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre studyDaniel J. Wallace, Caroline Gordon, Vibeke Strand et al.|Annals of the Rheumatic Diseases|2013Cited by 340
Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled TrialsMegan E. B. Clowse, Daniel J. Wallace, Richard Furie et al.|Arthritis & Rheumatology|2016Cited by 237